Tom M. Ganten

Sirolimus Use in Liver Transplant Recipients With Hepatocellular Carcinoma

Edward K. Geissler, Andreas A. Schnitzbauer, C. Zülke et al. · Transplantation · 2015 · 417 citations · Full text

Pharmacy, Oncology, Pharmacotherapy +17

Yes and PI3K Bind CD95 to Signal Invasion of Glioblastoma

Susanne Kleber, Ignacio Sancho-Martinez, Alexandra Beisel et al. · Cancer Cell · 2008 · 298 citations · Full text

Medicine, Cell Biology, Oncology +14

Preclinical Differentiation between Apparently Safe and Potentially Hepatotoxic Applications of TRAIL Either Alone or in Combination with Chemotherapeutic Drugs

Tom M. Ganten, Ronald Koschny, Jaromir Sykora et al. · Clinical Cancer Research · 2006 · 213 citations · Full text

Life Sciences, Pharmacology, Toxicology +17

Cancer Cell-Autonomous TRAIL-R Signaling Promotes KRAS-Driven Cancer Progression, Invasion, and Metastasis

Silvia von Karstedt, Annalisa Conti, Max Nobis et al. · Cancer Cell · 2015 · 194 citations · Full text

Medicine, Cancer Biology, Oncology +14

Enhanced caspase-8 recruitment to and activation at the DISC is critical for sensitisation of human hepatocellular carcinoma cells to TRAIL-induced apoptosis by chemotherapeutic drugs

Tom M. Ganten, Tobias L. Haas, J Sýkora et al. · Cell Death and Differentiation · 2004 · 193 citations

Life Sciences, Oncology, Pharmacology +15